JP/CALL/INNOVENT BIOLOGICS/45.05/0.02/09.09.24 Stock JP/CALL/INNOVENT BIOLOGICS/45.05/0.02/09.09.24
Add to a list
To use this feature you must be a member
Log inSign up

JP/CALL/INNOVENT BIOLOGICS/45.05/0.02/09.09.24 Stock

Warrant

20202

NLJPMSP0RGG6

Market Closed - Hong Kong S.E. 04:00:00 2024-06-06 am EDT
0.034 HKD -17.07% Intraday chart for JP/CALL/INNOVENT BIOLOGICS/45.05/0.02/09.09.24
1 month-63.44%
3 months-68.22%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Chart INNOVENT BIOLOGICS, INC.
Chart JP/CALL/INNOVENT BIOLOGICS/45.05/0.02/09.09.24

Latest news about INNOVENT BIOLOGICS, INC.

Innovent Biologics, Inc. Presents at 2024 ASCO Annual Meeting on Clinical Data of Anti-CLDN18.2 ADC in Patients with Advanced Pancreatic Cancer or Biliary Tract Cancer CI
Innovent Biologics, Inc. Announces Data from Pivotal Phase 2 TRUST-I Study of Taletrectinib (ROS1 Inhibitor) Publishes in JCO and Reports at 2024 ASCO Annual Meeting CI
Innovent Biologics, Inc. Presents Phase 1 Clinical Data of First-In-Class PD-1/IL-2a Bispecific Antibody Fusion Protein in Melanoma, Colorectal Cancer and Other Solid Tumors at 2024 ASCO Annual Meeting CI
Innovent Announces Picankibart Achieved Primary Endpoints in a Phase 3 Clinical Trial in Treating Moderate to Severe Plaque Psoriasis, and Plans to Submit NDA to the NMPA AQ
More news

Quotes 5-day view

Date Price Change
24-06-06 0.034 -17.07%
24-06-05 0.041 -2.38%
24-06-04 0.042 +55.56%
24-06-03 0.027 -18.18%
24-05-31 0.033 -2.94%

Delayed Quote Hong Kong S.E.

Last update June 06, 2024 at 04:00 am EDT

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying INNOVENT BIOLOGICS, INC.
Issuer J.P. Morgan
20202
ISINNLJPMSP0RGG6
Date issued 2023-09-25
Strike 45.05 $
Maturity 2024-09-09 (95 Days)
Parity 50 : 1
Emission price 0.183 $
Emission volume N/A
Settlement Por diferencias
Currency HKD

Technical Indicators

Highest since issue 0.3 $
Lowest since issue 0.027 $
Delta0.29x
Omega 6.100
Premium30.7x
Gearing21.34x
Moneyness 0.7936
Difference Strike 9.3 $
Difference Strike %+20.64%
Spread 0.001 $
Spread %2.94%
Theoretical value 0.0335
Implied Volatility 59.82 %
Total Loss Probability 80.81 %
Intrinsic value 0.000000
Present value 0.0335
Break even 46.73 $
Theta-0x
Vega0x
Rho0x

Company Profile

Innovent Biologics Inc is an investment holding company principally engaged in biopharmaceuticals. The Company and its subsidiaries are engaged in research and development of antibody and protein medicine products, sale and distribution of pharmaceutical products, and provision of consultation and research and development services. The Company's main product is Tyvyt (sintilimab injection), which is used to treat relapsed or refractory classical Hodgkin’s lymphoma. The Company's products also include adalimumab biosimilar IBI-303, which is used to treat rheumatoid arthritis, ankylosing spondylitis and psoriasis. Bevacizumab biosimilar IBI-305 is used to treat metastatic colorectal cancer and advanced, metastatic or recurrent non-small-cell lung cancer (NSCLC). Rituximab biosimilar IBI-301 is used to treat non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Its products are used in oncology, metabolic, immunology and ophthalmology diseases.
Sector
-
More about the company

Ratings for Innovent Biologics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Consensus: Innovent Biologics, Inc.

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
27
Last Close Price
34.42 CNY
Average target price
51.13 CNY
Spread / Average Target
+48.54%
Consensus
  1. Stock Market
  2. Warrants
  3. 20202 Warrant